Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
Lars Wallentin(Uppsala University), Stuart J. Connolly(Population Health Research Institute), Marcus Flather(Norfolk and Norwich University Hospital), Marco Alings(Utrecht University), Sean Yang(Population Health Research Institute), Jonas Oldgren(Uppsala University), Prem Pais(St.John's Medical College Hospital), John W. Eikelboom(Population Health Research Institute), Antonio Dans(University of the Philippines Manila), Maria Grazia Franzosi(Goethe University Frankfurt), Janice Pogue(McMaster University), Salim Yusuf(Population Health Research Institute), Paul Reilly(Boehringer Ingelheim (United States)), Michael D. Ezekowitz(Lankenau Institute for Medical Research)
Cited by 1,010
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
|Stroke|2014|5.2k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k